Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Lonza will enter the sterile drug fill-and-finish business by acquiring a Novartis facility in Stein, Switzerland. The facility includes liquid and lyophilized dosage-form capacity for clinical and commercial supply. Lonza will produce for Novartis and for third parties. The deal continues a trend among pharmaceutical services firms to build up finished-drug manufacturing capacity. Last month Catalent said it will acquire Bristol-Myers Squibb’s solid, biologics, and sterile product facility in Anagni, Italy.
This article has been sent to the following recipient: